ZA869573B - Ribosome-inactivating glycoproteins,modified by oxidation of their osidic units and reduction,and in-vivo prolonged-action immunotoxins containing such a glycoprotein - Google Patents

Ribosome-inactivating glycoproteins,modified by oxidation of their osidic units and reduction,and in-vivo prolonged-action immunotoxins containing such a glycoprotein

Info

Publication number
ZA869573B
ZA869573B ZA869573A ZA869573A ZA869573B ZA 869573 B ZA869573 B ZA 869573B ZA 869573 A ZA869573 A ZA 869573A ZA 869573 A ZA869573 A ZA 869573A ZA 869573 B ZA869573 B ZA 869573B
Authority
ZA
South Africa
Prior art keywords
ribosome
glycoprotein
oxidation
modified
reduction
Prior art date
Application number
ZA869573A
Inventor
Pierre Casellas
Bernard Bourrie
Xavier Canat
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ZA869573B publication Critical patent/ZA869573B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Botany (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA869573A 1985-12-20 1986-12-19 Ribosome-inactivating glycoproteins,modified by oxidation of their osidic units and reduction,and in-vivo prolonged-action immunotoxins containing such a glycoprotein ZA869573B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8518982A FR2591895B1 (en) 1985-12-20 1985-12-20 LONG-LASTING IN VIVO IMMUNOTOXINS HAVING MODIFIED RICIN A CHAIN ON ITS POLYSACCHARIDE PATTERNS

Publications (1)

Publication Number Publication Date
ZA869573B true ZA869573B (en) 1987-08-26

Family

ID=9326039

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA869573A ZA869573B (en) 1985-12-20 1986-12-19 Ribosome-inactivating glycoproteins,modified by oxidation of their osidic units and reduction,and in-vivo prolonged-action immunotoxins containing such a glycoprotein

Country Status (3)

Country Link
AR (1) AR242590A1 (en)
FR (1) FR2591895B1 (en)
ZA (1) ZA869573B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ218460A (en) * 1985-11-29 1989-07-27 Univ Melbourne Ricin-antibody conjugate
US6610299B1 (en) 1989-10-19 2003-08-26 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
DE4106389A1 (en) * 1991-02-28 1992-09-03 Behringwerke Ag FUSION PROTEINS FOR PRODRUG ACTIVATION, THEIR PRODUCTION AND USE
US7241595B2 (en) 1989-10-20 2007-07-10 Sanofi-Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US6475486B1 (en) 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47372A (en) * 1975-05-27 1979-10-31 Yeda Res & Dev Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same
JPS5843926A (en) * 1981-09-08 1983-03-14 Suntory Ltd Selective carcinostatic agent
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates

Also Published As

Publication number Publication date
FR2591895B1 (en) 1988-08-26
AR242590A1 (en) 1993-04-30
FR2591895A1 (en) 1987-06-26

Similar Documents

Publication Publication Date Title
GR861228B (en) Ascorbic acid derivatives production and use therefor
GB2142722B (en) Sampling human breath
IL81175A0 (en) Human preproinsulin-like factor i
GB2180203B (en) Folding wheelchairs
GB8624033D0 (en) Skin care composition
ZA918140B (en) Recovery of platinum group metals and gold by synergistic reaction between allylalkylthionocarbamates and dithiophosphates
GB8528183D0 (en) Titanium-base alloy
GB2186291B (en) Alloy and product made therefrom
NZ218552A (en) Trousers and overtrousers assembly fastened together at waistline
ZA869573B (en) Ribosome-inactivating glycoproteins,modified by oxidation of their osidic units and reduction,and in-vivo prolonged-action immunotoxins containing such a glycoprotein
AU6663086A (en) Ribosome inactivating glycoproteins, modified by oxidation of their osidic units and formation of a schiff's base and in-vivo prolonged-action immunotoxins containing such a glycoprotein
GB8715489D0 (en) Skin care compositions
AU6662986A (en) Ribosome-inactivating glycoproteins, modified by oxydation of their osidic units and reduction, and in vivo prolonged- action immunotoxins containing such a glycoprotein
GB8503654D0 (en) Human skin substitute
GB2184457B (en) Gold alloy
ZA869572B (en) Ribosome-inactivating glycoproteins,modified by oxidation of their osidic units and formation of a schiff's base and in-vivo prolonged-action immunotoxins containing such a glycoprotein
GB8627080D0 (en) Shampoo
GB8624917D0 (en) Titanium-base alloy
GB8504217D0 (en) Skin care product
GB8505417D0 (en) Folding garment rail
GB8826282D0 (en) Improved balloon design & application
GB8514732D0 (en) Purified immunoglobulin-related factor
GB2170990B (en) Bracelet or strap adjustment link
GB2181655B (en) Respirator bag
IL80629A0 (en) Dietary supplement